Cassava Sciences, Inc. (SAVA)
NASDAQ: SAVA · Real-Time Price · USD
2.160
+0.010 (0.47%)
At close: Sep 5, 2025, 4:00 PM
2.190
+0.030 (1.39%)
After-hours: Sep 5, 2025, 7:48 PM EDT
Cassava Sciences Employees
Cassava Sciences had 30 employees as of December 31, 2024. The number of employees increased by 1 or 3.45% compared to the previous year.
Employees
30
Change (1Y)
1
Growth (1Y)
3.45%
Revenue / Employee
n/a
Profits / Employee
-$4,105,567
Market Cap
104.35M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 30 | 1 | 3.45% |
Dec 31, 2023 | 29 | 3 | 11.54% |
Dec 31, 2022 | 26 | 2 | 8.33% |
Dec 31, 2021 | 24 | 13 | 118.18% |
Dec 31, 2020 | 11 | 2 | 22.22% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
SAVA News
- 24 days ago - Cassava Reports Q2 2025 Financials Results and Provides Business Update - GlobeNewsWire
- 4 weeks ago - Cassava Sciences Appoints Dr. Joseph Hulihan as Chief Medical Officer - GlobeNewsWire
- 4 weeks ago - Cassava Sciences Reports Positive Preclinical Study Evaluating Simufilam for TSC-Related Epilepsy - GlobeNewsWire
- 2 months ago - Cassava Presents Promising Preclinical Simufilam Data at TSC Alliance Meeting - GlobeNewsWire
- 4 months ago - Cassava Appoints Angélique Bordey, PhD, to Enhance Preclinical Program in TSC - GlobeNewsWire
- 4 months ago - Cassava Announces Retirement of Chief Medical Officer, Dr. Jim Kupiec, and Appointment of Dr. Jack Moore as Senior Vice President, Clinical Development - GlobeNewsWire
- 5 months ago - Cassava Sciences must face malicious prosecution lawsuit over Alzheimer's drug - Reuters
- 5 months ago - Cassava Sciences Discontinues Developing Simufilam For Alzheimer's After Another Phase 3 Trial Flop - Benzinga